M&A 'boom' to continue with spate of U.S.-foreign buyouts

Industry experts are saying Sanofi-Aventis' $20 billion buyout of Genzyme is just the latest in a "multiyear boom of M&A activity" in the pharma business. And they expect an "off the charts" flow of U.S. companies buying foreign pharma businesses. Report